MYX Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.75 |
| 52 Week High | AU$7.46 |
| 52 Week Low | AU$3.74 |
| Beta | 1.25 |
| 1 Month Change | 13.64% |
| 3 Month Change | 3.71% |
| 1 Year Change | -24.48% |
| 3 Year Change | -16.67% |
| 5 Year Change | -48.92% |
| Change since IPO | -60.42% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb
Sep 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 06Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
Dec 03Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Dec 01Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
Apr 12Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 01We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
Nov 16Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Nov 10Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
May 17Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Mar 22How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?
Mar 01What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition
Feb 08Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit
Jan 18Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares
Dec 27Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?
Dec 09
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation
Nov 24Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.5% | -4.9% | -2.7% |
| 1Y | -24.5% | -9.3% | 6.5% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: MYX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MYX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market cap | AU$385.45m |
| Earnings (TTM) | -AU$168.62m |
| Revenue (TTM) | AU$388.40m |
1.0x
P/S Ratio-2.3x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$388.40m |
| Cost of Revenue | AU$169.62m |
| Gross Profit | AU$218.78m |
| Other Expenses | AU$387.39m |
| Earnings | -AU$168.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 56.33% |
| Net Profit Margin | -43.41% |
| Debt/Equity Ratio | 7.0% |
How did MYX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 22:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mayne Pharma Group Limited is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | APP Securities Pty Ltd. |
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |